Victory Capital Management Inc. lowered its position in shares of Eidos Therapeutics Inc (NASDAQ:EIDX) by 11.1% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 183,170 shares of the company’s stock after selling 22,850 shares during the quarter. Victory Capital Management Inc.’s holdings in Eidos Therapeutics were worth $4,295,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also recently bought and sold shares of EIDX. New York State Common Retirement Fund purchased a new position in Eidos Therapeutics in the 4th quarter valued at approximately $69,000. BNP Paribas Arbitrage SA purchased a new position in Eidos Therapeutics in the 1st quarter valued at approximately $80,000. Oppenheimer Asset Management Inc. purchased a new position in Eidos Therapeutics in the 4th quarter valued at approximately $104,000. Bank of New York Mellon Corp purchased a new position in Eidos Therapeutics in the 3rd quarter valued at approximately $137,000. Finally, Virtus ETF Advisers LLC purchased a new position in Eidos Therapeutics in the 4th quarter valued at approximately $271,000. 31.63% of the stock is currently owned by hedge funds and other institutional investors.
EIDX has been the subject of a number of recent research reports. BMO Capital Markets initiated coverage on shares of Eidos Therapeutics in a research note on Friday, February 22nd. They issued an “outperform” rating and a $28.00 price objective for the company. Zacks Investment Research lowered shares of Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. BTIG Research initiated coverage on shares of Eidos Therapeutics in a research note on Wednesday, April 17th. They issued a “buy” rating and a $38.00 price objective for the company. Finally, JPMorgan Chase & Co. upgraded shares of Eidos Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Wednesday, February 27th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $30.29.
Eidos Therapeutics stock traded up $2.38 during mid-day trading on Friday, reaching $29.64. The company’s stock had a trading volume of 163,570 shares, compared to its average volume of 125,232. Eidos Therapeutics Inc has a 12-month low of $8.89 and a 12-month high of $29.83. The firm has a market capitalization of $1.09 billion and a price-to-earnings ratio of -15.94. The company has a current ratio of 19.04, a quick ratio of 19.04 and a debt-to-equity ratio of 0.01.
Eidos Therapeutics (NASDAQ:EIDX) last released its quarterly earnings data on Monday, April 15th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). On average, equities research analysts forecast that Eidos Therapeutics Inc will post -1.51 EPS for the current year.
In other news, insider Jonathan C. Fox sold 5,000 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $25.03, for a total transaction of $125,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christine Siu sold 11,913 shares of the business’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $19.66, for a total transaction of $234,209.58. The disclosure for this sale can be found here. Insiders have sold a total of 31,913 shares of company stock valued at $732,760 over the last 90 days.
Eidos Therapeutics Company Profile
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Featured Article: Trading Ex-Dividend
Want to see what other hedge funds are holding EIDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eidos Therapeutics Inc (NASDAQ:EIDX).
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.